Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Epigenomics AG: strategic in vitro diagnostics partnership with Abbott Molecular

27 Sep 2007 - Collaboration focuses on development and global commercialization of a molecular diagnostic test for the early detection of colorectal cancer.
 
Abbott obtains non-exclusive worldwide rights to Epigenomics' proprietary DNA methylation biomarker Septin 9
 
Anticipate European market launch in 2009; filing for U.S. approval in 2010
 
Epigenomics to receive an up-front fee, milestone payments and royalties
 
Option to expand partnership on multiple Epigenomics biomarkers to other cancer indications Epigenomics AG has signed a non-exclusive strategic collaboration and license agreement in molecular diagnostics with Abbott, a global healthcare company. Under the agreement, Abbott and Epigenomics intend to develop an in vitro diagnostic blood test for the early detection of colorectal cancer based on Epigenomics' proprietary DNA methylation biomarker Septin 9. The companies anticipate launching a CE-marked test in Europe in 2009 followed by regulatory filing for U.S. approval in 2010. Under the terms of the agreement, Epigenomics will receive an up-front fee, milestone payments and royalties on product sales. The agreement also contains provisions for the evaluation by Abbott of some of Epigenomics' other proprietary biomarkers for additional cancer indications.